YU37401A - Novi postupak tretmana - Google Patents
Novi postupak tretmanaInfo
- Publication number
- YU37401A YU37401A YU37401A YU37401A YU37401A YU 37401 A YU37401 A YU 37401A YU 37401 A YU37401 A YU 37401A YU 37401 A YU37401 A YU 37401A YU 37401 A YU37401 A YU 37401A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- treatment
- insulin sensitiser
- diabetes mellitus
- plasma
- novel method
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
- 230000036470 plasma concentration Effects 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 3
- 108090001061 Insulin Proteins 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 3
- 231100000489 sensitizer Toxicity 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Postupak za tretman dijabetes melitusa tipa 2 i stanja združenih sa dijabetes melitusom, koji postupak obuhvata unošenje u čoveka ili sisara ne-čoveka kome je to potrebno, efikasne netoksične količine sensitizera insulina tako da se obezbedi koncentracija plazme sensitizera insulina od bar nivoa praga ("koncentracija praga plazme") unutar opsega efikasnih nivoa plazme sensitizera insulina, preparati za korišćenje u takvom postupku i metodologija za odredjivanje koncentracija plazme aktivnog agensa korišćenog u takvim postupcima.[A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof, of an effective non-toxic amount of an insulin sensitiser so as to provide a plasma concentration of the insulin sensitiser of at least a threshold level (the "Threshold Plasma Concentration") from within the range of effective plasma levels of the insulin sensitiser, compositions for use in such method and methodology for determining plasma concentrations of active agent use in such methods.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9824893.3A GB9824893D0 (en) | 1998-11-12 | 1998-11-12 | Novel method of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU37401A true YU37401A (sh) | 2005-07-19 |
| RS50130B RS50130B (sr) | 2009-03-25 |
Family
ID=10842389
Country Status (40)
| Country | Link |
|---|---|
| EP (2) | EP1135128B1 (sh) |
| JP (1) | JP2003521455A (sh) |
| KR (2) | KR20070048279A (sh) |
| CN (3) | CN1235586C (sh) |
| AP (2) | AP2005003432A0 (sh) |
| AR (2) | AR029149A1 (sh) |
| AT (1) | ATE366573T1 (sh) |
| AU (1) | AU768303B2 (sh) |
| BG (2) | BG110061A (sh) |
| BR (1) | BR9915284A (sh) |
| CA (1) | CA2350425C (sh) |
| CO (1) | CO5150158A1 (sh) |
| CY (1) | CY1106892T1 (sh) |
| CZ (1) | CZ299801B6 (sh) |
| DE (1) | DE69936533T2 (sh) |
| DK (1) | DK1135128T3 (sh) |
| DZ (1) | DZ2938A1 (sh) |
| EA (2) | EA009192B1 (sh) |
| ES (1) | ES2289833T3 (sh) |
| GB (1) | GB9824893D0 (sh) |
| HK (1) | HK1041202B (sh) |
| HR (1) | HRP20010344B1 (sh) |
| HU (1) | HUP0104262A3 (sh) |
| IL (1) | IL143088A0 (sh) |
| MA (1) | MA26759A1 (sh) |
| MY (1) | MY128347A (sh) |
| NO (1) | NO328391B1 (sh) |
| NZ (1) | NZ527132A (sh) |
| OA (1) | OA12193A (sh) |
| PE (1) | PE20001239A1 (sh) |
| PL (1) | PL349421A1 (sh) |
| PT (1) | PT1135128E (sh) |
| RS (1) | RS50130B (sh) |
| SK (1) | SK286357B6 (sh) |
| TR (1) | TR200101348T2 (sh) |
| TW (1) | TWI234456B (sh) |
| UA (1) | UA79730C2 (sh) |
| UY (2) | UY25797A1 (sh) |
| WO (1) | WO2000027341A2 (sh) |
| ZA (1) | ZA200103793B (sh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
| JP2005514399A (ja) * | 2001-12-21 | 2005-05-19 | スミスクライン ビーチャム コーポレーション | ＰＰＡＲγアクチベーターの投薬法 |
| WO2012074375A1 (en) * | 2010-12-01 | 2012-06-07 | N.V. Nutricia | Prevention or treatment of overweight and obesity in type 2 diabetic patients |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| US4582839A (en) * | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH06779B2 (ja) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
| US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
| ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US4791125A (en) * | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
| MX15171A (es) * | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
| WO1989008650A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| GB8919417D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
| JPH0469331A (ja) * | 1990-07-10 | 1992-03-04 | Asahi Chem Ind Co Ltd | 徐放性エマルジョン製剤 |
| JP2572673B2 (ja) * | 1990-07-25 | 1997-01-16 | エスエス製薬株式会社 | 徐放性錠剤 |
| JPH04210683A (ja) * | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
| US5183823A (en) * | 1991-04-11 | 1993-02-02 | Takeda Chemical Industries, Ltd. | Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents |
| FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ATE151634T1 (de) * | 1991-08-26 | 1997-05-15 | Upjohn Co | Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5506245A (en) * | 1992-10-12 | 1996-04-09 | Adir Et Compagnie | Thiazolidinedione compounds |
| US5478853A (en) * | 1992-10-12 | 1995-12-26 | Adir Et Compagnie | Thazolidinedione compounds |
| CA2115587A1 (en) * | 1993-02-18 | 1994-08-19 | Hayato Kihara | Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles |
| DE4317320A1 (de) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| RU2195282C2 (ru) * | 1993-09-15 | 2002-12-27 | Санкио Компани Лимитед | Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm) |
| US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| US5708012A (en) * | 1995-04-28 | 1998-01-13 | Sankyo Company, Limited | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
-
1998
- 1998-11-12 GB GBGB9824893.3A patent/GB9824893D0/en not_active Ceased
-
1999
- 1999-11-10 DZ DZ990238A patent/DZ2938A1/xx active
- 1999-11-10 AR ARP990105700A patent/AR029149A1/es unknown
- 1999-11-10 AR ARP990105701A patent/AR029317A1/es unknown
- 1999-11-11 MY MYPI99004899A patent/MY128347A/en unknown
- 1999-11-12 CZ CZ20011656A patent/CZ299801B6/cs not_active IP Right Cessation
- 1999-11-12 CA CA002350425A patent/CA2350425C/en not_active Expired - Fee Related
- 1999-11-12 AU AU17196/00A patent/AU768303B2/en not_active Ceased
- 1999-11-12 UA UA2001053164A patent/UA79730C2/uk unknown
- 1999-11-12 AP AP2005003432A patent/AP2005003432A0/xx unknown
- 1999-11-12 PL PL99349421A patent/PL349421A1/xx not_active Application Discontinuation
- 1999-11-12 PE PE1999001148A patent/PE20001239A1/es not_active Application Discontinuation
- 1999-11-12 WO PCT/US1999/026746 patent/WO2000027341A2/en not_active Ceased
- 1999-11-12 AP APAP/P/2001/002137A patent/AP1580A/en active
- 1999-11-12 KR KR1020077009372A patent/KR20070048279A/ko not_active Ceased
- 1999-11-12 JP JP2000580572A patent/JP2003521455A/ja active Pending
- 1999-11-12 BR BR9915284-3A patent/BR9915284A/pt not_active Application Discontinuation
- 1999-11-12 EP EP99960293A patent/EP1135128B1/en not_active Expired - Lifetime
- 1999-11-12 UY UY25797A patent/UY25797A1/es not_active Application Discontinuation
- 1999-11-12 CN CNB998154806A patent/CN1235586C/zh not_active Expired - Fee Related
- 1999-11-12 EA EA200100539A patent/EA009192B1/ru not_active IP Right Cessation
- 1999-11-12 OA OA00100118A patent/OA12193A/en unknown
- 1999-11-12 DK DK99960293T patent/DK1135128T3/da active
- 1999-11-12 CO CO99071567A patent/CO5150158A1/es unknown
- 1999-11-12 CN CNA2008100058350A patent/CN101244062A/zh active Pending
- 1999-11-12 AT AT99960293T patent/ATE366573T1/de active
- 1999-11-12 RS YUP-374/01A patent/RS50130B/sr unknown
- 1999-11-12 TR TR2001/01348T patent/TR200101348T2/xx unknown
- 1999-11-12 PT PT99960293T patent/PT1135128E/pt unknown
- 1999-11-12 DE DE69936533T patent/DE69936533T2/de not_active Expired - Lifetime
- 1999-11-12 SK SK642-2001A patent/SK286357B6/sk not_active IP Right Cessation
- 1999-11-12 HU HU0104262A patent/HUP0104262A3/hu unknown
- 1999-11-12 EA EA200700968A patent/EA200700968A1/ru unknown
- 1999-11-12 HK HK02101081.6A patent/HK1041202B/en not_active IP Right Cessation
- 1999-11-12 EP EP06124048A patent/EP1759698A1/en not_active Withdrawn
- 1999-11-12 NZ NZ527132A patent/NZ527132A/en not_active IP Right Cessation
- 1999-11-12 KR KR1020017006028A patent/KR20010080440A/ko not_active Ceased
- 1999-11-12 ES ES99960293T patent/ES2289833T3/es not_active Expired - Lifetime
- 1999-11-12 CN CNA2005101201583A patent/CN1771943A/zh active Pending
- 1999-11-12 IL IL14308899A patent/IL143088A0/xx unknown
- 1999-11-12 HR HR20010344A patent/HRP20010344B1/xx not_active IP Right Cessation
- 1999-11-15 UY UY25801A patent/UY25801A1/es not_active Application Discontinuation
- 1999-12-24 TW TW088122851A patent/TWI234456B/zh not_active IP Right Cessation
-
2001
- 2001-05-10 ZA ZA200103793A patent/ZA200103793B/en unknown
- 2001-05-10 NO NO20012301A patent/NO328391B1/no not_active IP Right Cessation
- 2001-05-11 MA MA26193A patent/MA26759A1/fr unknown
- 2001-06-07 BG BG110061A patent/BG110061A/bg unknown
- 2001-06-07 BG BG105569A patent/BG65577B1/bg unknown
-
2007
- 2007-09-27 CY CY20071101240T patent/CY1106892T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200735890A (en) | Compositions and methods for increasing insulin sensitivity | |
| DE3569836D1 (en) | Disinfecting method and compositions | |
| WO1998046588A3 (en) | Compounds and therapies for the prevention of vascular and non-vascular pathologies | |
| AP2001002291A0 (en) | Novel method of treatment. | |
| ID30237A (id) | KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES | |
| AU2001293851A1 (en) | Stabilized hydrogen peroxide solutions | |
| MIYAZAKI et al. | Interaction of drugs with bile components. I. Effects of bile salts on the dissolution behavior of indomethacin and phenylbutazone | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| KR900002789A (ko) | 안과용 용액을 보존하는 방법 및 이를 위한 조성물 | |
| ID27765A (id) | Plester gel yang mengandung steroid dan proses pembuatannya | |
| EA200200502A1 (ru) | Способ введения ингибитора фосфодиэстеразы 4 | |
| NZ600269A (en) | Delivery device for treatment of mastitis | |
| MY128347A (en) | Novel method of treatment. | |
| AU2001259801A1 (en) | 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same | |
| AP2000001735A0 (en) | Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. | |
| BR9915214A (pt) | Combinações contendo um beta-agonista e umagente anti-diabético adicional | |
| MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
| ECSP993217A (es) | Nuevo metodo tratamiento vii | |
| AU2002211577A1 (en) | Protecting therapeutic compositions from host-mediated inactivation | |
| MXPA04000517A (es) | Medicamentos profilacticos de ascitis para aves de corral. | |
| JPS5762218A (en) | Ophthalmic solution | |
| NZ503862A (en) | Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia | |
| AU2001242398A1 (en) | Contact lens treating method and composition | |
| TR200000957T2 (tr) | Hiperglisemi tedavisinde tiazolidinedion kullanımı | |
| JPS53141354A (en) | Non-toxic stabilized olefinic high polymer composition |